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Background: CSIC (5-chloro-3-phenylsulfonylindole-2-carboxamide), a non-nucleoside reverse transcriptase inhibitor
(NNRTI) has not been advanced as a therapeutic anti-HIV candidate drug due to its low aqueous solubility and poor
bioavailability.
Objective: The objective of this work was to formulate CSIC into self-emulsifying oil formulations for the purpose
of improving its aqueous solubility and evaluating in vitro antiretroviral activity.
Methods: CSIC self-emulsifying oil formulations (SEFs) were formulated and evaluated for droplet size, zeta
potential, polydispersity index (PDI), viscosity, emulsification time, stability and bioactivity.
Results: Results showed significantly improved solubility of CSIC in the SEFs.The concentration of co-surfactant
affected the droplet size, zeta potential and polydispersity index. In vitro bioactivity studies showed that the CSIC
SEFs retained full anti-HIV activity.
Conclusion: The in vitro data from this first attempt to formulate CSIC SEFs suggest that improvement on the aqueous
solubility of CSIC through this delivery system may accentuate its antiretroviral effectiveness in vivo via bioavailability
enhancement. The formulation is therefore intended as an oral anti-HIV agent for prophylactic and therapeutic uses.
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Approximately 40% of all new drug entities have poor
aqueous solubility characteristics [1]. Specific to the HIV
field a number of newly developed drug candidates
including several non nucleoside reverse transcriptase
are extremely hydrophobic. Poorly soluble drugs tend to
exhibit low bioavailability, high intra- and inter-subject
variability, and a lack of dose proportionality, which pose a
significant challenge when administered per orally [2,3].
Drugs that belong to the Class II Biopharmaceutic classifi-
cation system are frequently caught up in this web of poor
solubility [4]. Enhancement of solubility has been achieved
by some drug manufacturers through use of special excipi-
ents or formulation carriers that enhance drug dissolution
and hence, bioavailability. Several approaches including,* Correspondence: obittenick@yahoo.com
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reproduction in any medium, provided the orsolid dispersions, inclusion complexes, nanoparticles or
lipid vehicles [4-6] are available as potential formulation
options for hydrophobic drug candidates. An additional
option is self-emulsifying oil formulation.
Self-emulsifying oil formulation (SEF) is a lipid compos-
ition with inherent capability of improving drug solubility
and bioavailability. SEF is a thermodynamically stable
isotropic mixture of oil, surfactant and co-surfactant, which
on gentle agitation in aqueous medium self-emulsifies to
yield micro or nano-emulsion [7,8]. SEF, in its native form
comes as anhydrous emulsion (emulsion pre-concentrate),
but upon dispersion in aqueous medium it transforms into
oil-in-water (O/W) or water-in-oil (W/O) micro-emulsion
or nano-emulsion which constitutes micro-domains of oil
droplets stabilized by the interfacial film created by the
surfactant and co-surfactant mixture [9,10].
The advantages of SEF over ordinary oil or surfactant
dispersions of drugs include the combination of permeability
and/or absorption enhancement, thermodynamic stabilityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tension and formation spontaneity), optical isotropy, ease of
sterilization via filtration, high surface area, very small
particle size (that promotes adherence to membranes)
[11] and the lipoid characteristic which promotes drug
intactness in the droplet prior to absorption. Long shelf
life, ease of scale-up and manufacturing, improvement
on dissolution and lymphatic transport of poorly soluble
or lipophilic drugs rate them better than other novel
colloidal drug delivery systems [7]. In the SEF front
there are commercially available SEF-based antiretroviral
drugs which, demonstrate the contribution of SEFs in bio-
availability enhancement. NorvirW (ritonavir), FortavaseW
(saquinavir) and AptivusW (tipranavir) are antiretroviral
drugs in the market which have been formulated based on
this approach [12,13]. The dose-limiting side effects
associated with hydrophobic antiretroviral drugs may
be mitigated if formulated in a SEF. This is because erratic
drug release common with poorly soluble drugs [2,3] may
sometimes lead to the utilization of excessively high drug
dose in traditional formulations. SEF ranks well as a
reliable carrier that promotes consistent absorption
and bioavailability of hydrophobic drugs [2,14].
NNRTIs such as efavirenz, UC781, dapivirine and 5-
chloro-3-phenylsulfonylindole-2-carboxamide (CSIC) are
potent tight-binding inhibitors of HIV RT, a property
that may enhance their utility in both therapeutic and
prophylactic use [15]. Efavirenz is poorly soluble, with
a bioavailability of 40-45% and belongs to class II
Biopharmaceutic classification system (BCS) [16-18].
Similarly CSIC is poorly soluble and has a limited bioavail-
ability which precludes its further development despite
superior in vitro cell-protective ability [15,19].
CSIC pretreatment of uninfected cells to protect them
from subsequent HIV infection in the absence of
exogenous drug, resulted to sequestration of CSIC in
the cell plasma membrane [15]. This may be suggest-
ive of possible high in vivo membrane permeability
[20-22]. Nonetheless, the poor aqueous solubility of
CSIC may restrict access to absorption through GIT
membrane. In this work SEF was explored as a for-
mulation strategy to overcome the limited aqueous
solubility and associated bioavailability limitations of
CSIC. This is because it offers a nano-sized non-ionic
molecular form of the soluble drug which enhances
permeability and absorption. Therefore, the objective
of this work was to formulate CSIC into SEFs for the
purpose of improving its aqueous solubility and evaluating
in vitro cell-based antiretroviral bioactivity.
Materials and methods
Materials
The excipients used included triacetin (Acros Organics
of Fisher Scientific, U.S.A), lauroglycol 90W (propyleneglycol monolaurate, Gattefosse, France), and LabrasolW
(caprylocaproyl macrogol-8-glycerides, Gattefosse, France).
CSIC was obtained from Dr. Michael Parniak at the
University of Pittsburgh.
Pseudo ternary phase diagram construction
LabrasolW (surfactant) and lauroglycol 90W (co-surfactant)
ratios were varied at five fixed triacetin (oil) ratios (0.5, 1.0,
1.5, 2.0 and 2.5) to generate 30 different oil/surfactant/
co-surfactant homogenous isotropic preconcentrate for-
mulations. Oil (triacetin) concentration was evaluated at
levels of 10, 20, 30, 40, and 50%. The remainder of the
formulations studied consisted of a combination of sur-
factant and co-surfactant. LabrasolW (surfactant) and
lauroglycol 90W (co-surfactant) were evaluated at levels
of 10 to 80%. The titration method was adopted for the
determination of self-emulsifying region. A 0.1 mL
quantity of the SEF was pipetted into a 10 mL beaker.
Drop-wise quantities of Milli-Q water (Millipore, USA)
filtered through a 0.22 micrometer filter were introduced
into the beaker until a stable transparent system was
formed. SEF formulations resulting in phase separation or
non-transparent emulsions were discarded. The different
amounts of the ingredients that contributed to transparent
SEFs were determined and a phase diagram plotted using
JMP version 4.0.4 software (SAS Institute Inc).
Assay of CSIC
A liquid chromatography method was used to assay
CSIC. A Waters Acquity UPLC was employed. A 1 mg
quantity of CSIC was dissolved in 5 mL of Acetonitrile.
From the stock solution serial dilutions were made
to attain the concentration range of 10, 20, 50, 100
and 150 μg/mL respectively. The corresponding Area
under the curve values and the resultant calibration
curve were determined using the UPLC machine
(Acquity UPLC,Waters USA). CSIC was separated with
a C18 (2.1 × 50 mm, 1.7 micrometer) column using a
mobile phase of 0.05 v/v% trifluoroacetic acid (TFA) in
acetonitrile and 0.08 v/v% of TFA in water at a flow
rate of 0.4 ml/min. UV detection was at 302 nm. CSIC
eluted at 6 min under these conditions.
Solubility of CSIC in triacetin
An excess quantity of CSIC was introduced into a vial
containing triacetin (oil). The suspension was first vortexed
for 10 min and subsequently mixed intermittently for 5 h
using a mechanical shaker, prior to storage for 24 h. Using
a 0.1 micrometer filter (Fisher Scientific, USA) 20 μL
of the suspension was double-filtered, diluted to 1 mL
with acetonitrile and assayed for CSIC content using
the UPLC method described above. A total of seven
replicate samples were analyzed.
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A 2–10 mg quantity of CSIC powder was sealed in a small
aluminum pan using a mechanical punch (Perkin Elmer,
USA). A sealed empty pan served as control over the
temperature range 30 - 400°C. The samples were analyzed
using the software, Pyris Series- DSC 7. DSC enabled the
determination of melting point of CSIC.
Formulation of CSIC SEFs
From the experiment described under pseudo ternary
phase diagram section the optimal SEF formulations
were identified as those which did not result in phase
separation and maintained transparency. These formula-
tions are detailed in Table 1. CSIC was combined with each
of these formulations at the ratio 0.5 mg CSIC/0.3 ml SEF.
Briefly, 0.5 mg CSIC was mixed with triacetin, and then the
appropriate amounts of surfactant and co-surfactant were
added sequentially with stirring until a homogenous mix
was achieved.
Characterization of CSIC SEFs
The content of CSIC in each formulation was determined.
In these studies a 0.3 mL quantity of SEF was sam-
pled from each of the five formulations described in
Table 1 and diluted to 1 mL with acetonitrile. After
shaking to ensure complete mixing, the mixtures were
assayed for CSIC content using the described UPLC
method. Each experiment was carried out in tripli-
cates. Additionally viscosity, droplet size, polydisper-
sity index and zeta potential were also determined for
each formulation. Viscosity was measured using 0.5 ml
samples with a DV-111 ultra programmable Rheometer
(Brookfield Engineering Labs, USA) equipped with a
CPE 51 Spindle. Data were calculated with Rheocalc
V3.1-2 software. Triplicate determinations were made.
A Malvern Zeta Sizer (Malvern Instruments Ltd., UK)
was used to determine droplet size, polydispersity index
and zeta potential. In these studies transparent emulsions
were prepared by gentle agitation of the anhydrous
SEF with an appropriate quantity of water. Droplet size
was evaluated using cuvette containing 2.5 ml of the
nano/microemulsion, and zeta potential was measuredTable 1 The % concentrations (w/w) of the different
components in stable and transparent emulsions
Formulation Oil:surfactant:
cosurfactant
Oil
(% w/w)
Surfactant/
cosurfactant
mix (%w/w)
Water
(%w/w)
A 10:80:10 1.2 8.6 90.2
B 10:70:20 1.8 12.5 85.7
C 20:70:10 2.7 8.5 88.8
D 20:60:20 2.7 8.4 88.9
E 30:60:10 5.4 9.8 84.8using 1 ml in capillary cuvettes. All measurements
were performed in triplicates.
Stability studies for CSIC SEFs
Stability testing for each of the CSIC formulations was
evaluated. In these studies each of the CSIC formulations
was introduced into vials and stored under three different
conditions: (1) 25°C and 60% relative humidity (RH) using
a Caron 6010 Humidity Chamber, (2) 40°C and 86% RH
using a Caron 6010 Humidity Chamber, and (3) 50°C
(Former Scientific Inc., U.S.A). Drug content was deter-
mined weekly over a four week period. Additionally stability
under stressed conditions was evaluated. Firstly, the effect
of centrifugation was studied to evaluate potential metasta-
ble conditions, including phase separation and/or drug
precipitation. This was done by centrifuging each CSIC
formulation at 2000 rpm for 30 min and visually observing
for phase separation and drug precipitation. Secondly, the
formulations were also stressed by temperature cycling. In
brief, the formulations were subjected to a cycle of 12 h
refrigeration (4°C) and 12 h storage at room temperature
(25°C) for a period of one week. Formulations were then
evaluated visually for phase separation or drug precipitation.
Emulsification time
An adaptation of the method of Koo et al. [23] was used.
A 0.3 mL quantity of the SEF was introduced into a beaker
containing 200 mL milli-Q water at 37°C. The sample was
stirred and visually monitored to determine the time for
complete emulsification.
Drug release/dispersion studies
Drug release/dispersion was measured using a Sotax
dissolution apparatus (Sotax CP 7, USA). The dissolution
chambers were filled with 100 mL 0.1 N HCl. Analyses
were carried out at 37°C and drug content evaluated at
3 min intervals over 40 min.
Bioactivity testing
Two types of bioactivity tests were carried out, (i) standard
antiviral assessments in which cells were simultaneously
exposed to varying concentrations of drug and HIV, with
drug being present throughout the infection process, and
(ii) protective or memory effect assessments in which cells
were pretreated with varying concentrations of drug for
16 h, then exogenous drug was removed by extensive
washing and the cells exposed to HIV in the absence of
exogenous drug. HIV replication was evaluated in single
replication cycle HIV assays, using P4R5 HIV infection indi-
cator cells (from Dr. John Mellors, University of Pittsburgh).
Cells were maintained in DMEM/10% FBS supplemented
with puromycin (0.5 g/mL). P4R5 cells express CD4,
CXCR4 and CCR5 as well as a β-galactosidase reporter
gene under the control of an HIV LTR promoter [24]. Viral
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P4R5 cells (5x103cells/well). Cells were inoculated with
25 ng HIV-1 p24/well and the extent of infection was
evaluated 48 h post-infection using fluorescence-based
β-galactosidase detection assay. Briefly, infected cells
were washed, then incubated with 100 L lysis buffer
(60 mM Na2HPO4, 40 mM NaH2PO4 (pH 7.2), 1 mM
MgSO4, 100 mM -mercaptoethanol, 2% [v/v] Triton X-100)
for 1 h at 37°C. β-Galactosidase activity was assessed
by addition of 50 L 4-MUG to a final concentration of
0.5 mM, incubation for 1 h at 37°C, and then quenched
with 150 L 0.2 M Na2CO3, pH 11.2. Fluorescence
intensity was assessed with a SPECTRA max GEMINI XS
dual-scanning micro-plate spectrofluorometer (Molecular
Devices, Sunnyvale, CA) using an excitation wavelength
of 355 nm and an emission wavelength of 480 nm, with
cutoff filter set to 475 nm.
Statistics
Results were presented as the mean ± standard deviation.
One-way analysis of variance (ANOVA) was employed in
the determination of statistical significance using Graph
Pad Instat Demo (Graph pad software, Inc., USA). P < 0.05
was considered statistically significant.
Results
Pseudo ternary phase diagram
Of the 30 formulations tested, only five (A-E) (Table 1)
formed transparent micro/nano-emulsions without phase
separation. These were evaluated as potential SEFs for
CSIC. The pseudo ternary phase diagram is an important
preliminary strategy adopted in SEFs to delineate self-
emulsifying regions [11]. Preparation of SEFs without a
preliminary phase diagram construction may result in loss
of formulation stability after a period of storage. The
pseudo ternary phase diagram is shown in Figure 1.Figure 1 Pseudo-ternary phase diagram for oil, surfactant mix
and water.Solubility, stability and drug content
The mean solubility of CSIC in triacetin was 0.75 ±
0.04 mg/mL. This limited the unit dose of the formulation
to 0.5 mg CSIC. Solubility assessments in the surfactants
were not done, since the triacetin oil component was the
primary determinant for the drug to remain intact in the
droplet post-emulsification. The drug content of the SEFs
was between 0.42-0.48 mg (83-93%) (Table 2). Studies to
evaluate the effect of temperature and relative humidity on
the stability of CSIC in the SEFs showed no substantial
changes in CSIC content over the 4 week duration of the
experiment (Table 3). Differential scanning calorimetry of
CSIC showed a melting peak of 243.67°C.
Droplet size, polydispersity index, zeta potential, viscosity
and emulsification time
One-Way Analysis of Variance (ANOVA)-based Tukey-
Kramer multiple comparisons Test showed that the droplet
sizes of placebo and drug-loaded formulations A, C and E
respectively were significantly (p < 0.05) smaller than those
of formulations B and D (Table 4). Furthermore ANOVA-
based Student-Newman-Keuls Multiple Comparisons Test
revealed that drug-loading did not significantly (p < 0.05)
affect the droplet sizes of the formulations in comparison
with placebo batches (Table 4). Placebo formulation D
showed significantly (p < 0.05) higher PDI values (Table 4)
than those of A, C and E, while B was only significantly
(p < 0.05) higher than C and E. Drug-loaded formulations A,
C and E recorded significantly (p < 0.05) lower PDI than B
and D. On the contrary, drug-loading did not significantly
(p < 0.05) contribute to increased PDI. Low polydispersity
indices are preferable as emulsions with higher values may
be prone to instability. Negative zeta potential often associ-
ated with oil-in-water emulsions was generally the case,
with minor variations amongst the batches. The viscosity
values of the SEFs were 51mpa.s, 48.8mpa.s, 44.3mpa.s,
37.8mpa.s, and 35.7mpa.s for formulations A through E
respectively. All formulations displayed a Newtonian flow
pattern. The rate of emulsification was too fast (within a
few seconds) to be accurately measured. The high rate of
emulsification precluded determination of a dissolution
profile, as the formulations showed 100% drug release
within the earliest time point measured (3 minutes).Table 2 Drug content (% CSIC recovery) in various SEFs
Formulation Oil:surfactant:
cosurfactant
Drug assay content
(mg) % recovery
A 10:80:10 0.468 ± 0.0006 93.62
B 10:70:20 0.436 ± 0.0028 87.12
C 20:70:10 0.453 ± 0.002 90.58
D 20:60:20 0.449 ± 0.0002 89.88
E 30:60:10 0.420 ± 0.001 83.98
Table 3 Thermal stability of CSIC in CSIC SEF
Amount of CSIC remaining (mg)
FC1 Week 0 Week 2 Week 3 Week 4
25°C 40°C 50°C 25°C 40°C 50°C 25°C 40°C 50°C
A 0.47 0.40 ± 0.01 0.45 ± 0.002 0.48 ± 0.02 0.36 ± 0.001 0.37 ± 0.01 0.39 ± 0.03 0.39 ± 0.04 0.47 ± 0.01 0.49 ± 0.03
B 0.44 0.40 ± 0.008 0.45 ± 0 0.50 ± 0.1 0.35 ± 0.01 0.37 ± 0.02 0.40 ± 0.01 0.39 ± 0.02 0.47 ± 0.02 0.47 ± 0.02
C 0.45 0.414 ± 0.001 0.50 ± 0.01 0.50 ± 0.1 0.36 ± 0 0.39 ± 0.01 0.38 ± 0.02 0.40 ± 0.003 0.48 ± 0.003 0.46 ± 0.02
D 0.45 0.42 ± 0.004 0.45 ± 0.01 0.46 ± 0.01 0.34 ± 0.02 0.39 ± 0.02 0.4 ± 0.01 0.42 ± 0.004 0.46 ± 0.01 0.50 ± 0.001
E 0.42 0.39 ± 0.001 0.44 ± 0.04 0.43 ± 0.01 0.34 ± 0.01 0.36 ± 0.01 0.38 ± 0.01 0.39 ± 0.001 0.44 ± 0.002 0.47 ± 0.005
1 = Formulation code.
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In order to establish that the formulation did not result
in loss of bioactivity, in vitro anti HIV testing was
conducted using the five formulations (A-E). Figure 2
illustrates the antiviral activity for each of the formula-
tions tested. This data showed that the formulations did
not result in any loss of antiretroviral bioactivity when
compared to unformulated drug substance. Furthermore,
the highest concentration tested in these experiments
was 0.5 μM. No toxicity was seen at this level indicating
that the SEFs did not result in increased toxicity at the
0.5 μM level of dosing. The “memory effect” of the SEFs
at 0.1, 1.0, and 10 μM was also tested. Cells were incu-
bated with these concentrations for 16 h, then washed
and exposed to HIV. All SEFs were very toxic at 10 μM,
and partially toxic at 1 μM. CSIC alone was not toxic at
any of these concentrations. All CSIC samples either
tested unformulated or in SEFs gave complete protection
without discernible toxicity at 0.1 μM. The potent pro-
tective or memory effect exerted by the SEFs at 0.1 μM
showed that the cells maintained ready access to the
formulated drug, essentially similar to that of the free
unformulated CSIC. On the contrary when the placebo
SEFs, were tested there was no anti-HIV activity.
Discussion
In this study it was found that higher oil and lower
surfactant ratios (eg, formulation D) provided a narrow
transition window from anhydrous to transparent nano-
emulsion than did lower oil and higher surfactant ratiosTable 4 Droplet size, zeta potential and polydispersity index
1FC Placebo nano/micro-emulsion
Droplet size
(nm)
Polydispersity
index
Zeta potential
(-)(mV)
A 40.36 ± 0.69 0.159 ± 0.001 0.635 ± 0.03
B 296.5 ± 54 0.432 ±0.16 0.979 ± 0.002
C 41.1 ± 0.23 0.134 ± 0.01 1.32 ± 0.02
D 288.5 ± 13 0.559 ± 0.02 1.51 ± 0.01
E 52.8 ± 1.4 0.136 ± 0.005 0.970 ± 0.002
1 = Formulation code.(eg, formulation A). Figure 1 clearly portrays a narrow
self-emulsifying region, since only a few formulations
formed stable micro/nano-emulsions upon titration with
water. Out of the 30 batches evaluated only 5 formed
transparent emulsions upon aqueous dilution. The rest ei-
ther witnessed phase separation or formed nontransparent
emulsions with outrageous droplet sizes. Thus they were
excluded. Our choice of the five stable batches was for
comparative purposes.
The determination of the amount of drug that could
be dissolved in the anhydrous emulsion is crucial to
avoid post-formulation drug precipitation either during
storage or following in vivo dispersion in the aqueous
GIT environment [21,25]. CSIC was found to dissolve
very slowly, but once dissolved in the anhydrous emulsion
it did not precipitate out. Dissolution in SEF involves
molecular interaction with the excipients that renders the
crystalline drug amorphous [26]. The 0.75 mg solubility in
triacetin motivated the choice of 0.5 mg per dose of
SEF. Our bioactivity studies results have confirmed 0.5 mg
as pharmacologically effective. However, establishment
of minimum effective concentration and unit dose is
anticipated in our next investigation.
Experimental evaluations of the thermodynamic stability
of SEFs are important to assess the possibility of drug
precipitation or phase separation after centrifugation or
repeated refrigeration/warming cycles. With conventional
emulsions, the index of stability is the absence of phase
separation after centrifugation [27], but in SEFs an
additional organoleptic index includes the presence/values for the nano/micro-emulsions
Drug-loaded nano/micro-emulsion
Droplet size
(nm)
Polydispersity
index
Zeta potential
(-)(mV)
67.84 ± 1.6 0.283 ± 0.001 0.635 ± 0.01
269 ± 6.1 0.533 ± 0.003 1.58 ± 0.07
58.6 ± 0.3 0.283 ± 0.004 1.72 ± 0.04
286 ± 11 0.587 ± 0.001 2.18 ± 0.08
65.39 ± 0.9 0.251 ± 0.003 2.25 ± 0.02
Figure 2 Antiviral activity of CSIC powder and CSIC SEF.
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thermodynamic stability both in the centrifugation
and refrigeration/warming cycle protocols. This may be a
clue that this formulation strategy is superior to macro-
emulsions or colloidal formulations [5,11]. Furthermore at
different temperature and humidity conditions CSIC
demonstrated stability in the SEFs. The high melting
point of CSIC (Figure 3) was an indication of thermal
stability or non-heat sensitivity. This may be why stability
studies lacked evidence of thermal drug degradation.Figure 3 DSC thermogram for CSIC.In all the formulations, as the concentrations of oil
and surfactant were simultaneously increased and de-
creased respectively, co-surfactant was held at a fixed
concentration of either 10% (formulations A, C, E) or
20% (formulations B, D) (Table 1). It thus appears that
droplet size may be related to the co-surfactant concentra-
tion used in the formulation; larger droplet sizes resulted
from 20% co-surfactant concentration. The contribution
of co-surfactant to droplet size may be connected to its
supportive functionality during emulsification, where it
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micro-emulsions, the interfacial tension is so low that
the interfacial energy assumes a similar or lower value
than the entropy of dispersion. This renders the free
energy zero or negative [28,29]. The use of only one
surfactant may hardly achieve transient negative inter-
facial tension and fluid interfacial film; hence the need
for incorporation of a co-surfactant [30]. Generally,
co-surfactants lower the interfacial bending stress and
consequently predispose the interfacial film to possess
enough flexibility to assume various curvatures required
for nano/micro-emulsion formation over a wide range of
compositions [11,31]. In addition, lauroglycol 90W has a
potential dual role of co-surfactant and oil. Higher co-
surfactant concentration may have simultaneously in-
creased the interfacial thickness and curvature flexibil-
ity of the emulsion droplets with consequent size
enlargement. Although the three constituents were
miscible, upon emulsification in aqueous phase the
cosurfactant with low HLB as the oil may have had better
interaction with the oil than the surfactant (with high HLB)
and the oil. The polar head of the surfactant may have pro-
truded towards and interacted more with the aqueous
medium.
During emulsification more work and energy may be
required for droplet formation in high drug-loaded than
placebo formulations. Apparently the placebo formulations
may ultimately offer lower resistance in aqueous medium
during the emulsification process and form smaller droplets
than the drug-loaded ones. However in this present
investigation the low drug loading (0.5 mg/dose) did not
impel significant droplet size or PDI increase [32] probably
because little resistance may have been posed.
The oil constituent of the SEFs may be responsible for
the negative zeta potential of the nano/micro-emulsions
[33]. The viscosity of SEFs is critical during dispersion in
aqueous phase. Higher viscosities tend to slow down the
emulsification rate which may be detrimental when
faster in vivo drug release and smooth post-absorption
bioavailability profiles are crucial. The low values
recorded by the SEF formulations in the present study
were low enough to preclude the possibility of erratic or
slow self-emulsification.
Self-emulsification occurs when the entropy change
favoring dispersion is more than the energy needed to
increase the surface area of the dispersion [34,35]. Two
minutes has been suggested as an upper acceptable
limit for emulsification time [23]; thus the SEFs of
the present work were well within this limit. High
emulsification rate was responsible for 100% drug release
within three minutes.
For an orally administered drug, gastrointestinal and
pharmaceutical barriers must be overcome before ab-
sorption can take place. Aqueous solubility of thedrug in question is a crucial factor because only drug
in solution is destined for possible absorption [26].
Since the dissolution rate is the rate-determining step
to absorption of poorly soluble drugs, improvement
on aqueous solubility will promote absorption and
bioavailability [4,36]. Consequently, only the relative
quantity of drug that emerges after systemic absorption
may be available at the receptor site for pharmacological
activity. The bioactivity investigation conducted within
this study attempted to predict the absorption status of
CSIC. It did not account for the in vivo gastrointestinal
interactions between drug, food and aqueous GIT fluid.
The unformulated CSIC had similar antiviral activity as
the CSIC SEF formulations. However the CSIC powder
was first dissolved in an aqueous solution of dimethyl
sulphoxide (DMSO) since it is poorly water soluble. Other-
wise, unaided dispersion in water would be unsolubilised
and difficult to acces the cells. This may be the predictable
in vivo fate when administered orally in that form. The
stock solution of the CSIC in DMSO was diluted with
excess water and vigorously shaken otherwise drug
crystallization would take place. Obviously our SEF
formulation offers a less tedious and more commercially
viable approach. Two important observations made in our
study indicated CSIC SEFs’ therapeutic and prophylactic
potentials. Bioactivity established at 0.5 μM and cell pro-
tection at, 0.1 μM essentially corroborate drug permeability
and activity within the cells. Consequently in the GIT the
formulation may witness smooth absorption via the villi of
the small intestine. Suffice it to say that of utmost signifi-
cance was the established improvement on CSIC aqueous
solubility which may overcome barrier to its further devel-
opment as an HIV therapeutic agent [15,19]. Poor water
solubility of some antiretroviral drugs may predispose to
impaired and inconsistent dissolution within the GIT and
consequent erratic absorption. This may cause delay in
reaching peak plasma concentration and predispose to
sublethal drug concentration. Subpharmacological concen-
trations may induce resistance. The burden of resistance
associated with some hydrophobic antiretrovirals may be
due to the above reason.
These studies suggest that this formulation approach
could address pharmaceutical product development
limitations for the anti-HIV drug candidate CSIC such
as poor aqueous solubility and cellular permeability.
Furthermore this formulation strategy provides a platform
which can be extended to other hydrophobic anti-retroviral
agents facilitating their advancement in development.
Conclusion
Further development of CSIC had been stalled due to
poor aqueous solubility and low bioavailability. However,
in these studies a self-emulsifying oil formulation has
been shown to be a reliable formulation approach for
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http://www.aidsrestherapy.com/content/10/1/14the improvement of CSIC aqueous solubility. The in vitro
antiretroviral bioactivity of the CSIC SEF formulations
developed was also established. We therefore conclude
that self-emulsifying oil formulation may provide improved
bioavailability for this poorly soluble drug making it a viable
drug candidate for evaluation in HIV therapy. Further
research works are ongoing in our laboratory. Areas of
further investigative concern include use of wider spectrum
of surfactants, cosurfactants and oils. Extensive stability and
bioavailability studies are also contemplated.
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